Lantheus Holdings, Inc. (LNTH): Price and Financial Metrics


Lantheus Holdings, Inc. (LNTH)

Today's Latest Price: $13.17 USD

0.17 (1.31%)

Updated Nov 27 1:00pm

Add LNTH to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

LNTH Stock Summary

  • LNTH's went public 5.43 years ago, making it older than only 19.26% of listed US stocks we're tracking.
  • LNTH's current price/earnings ratio is 2,234.78, which is higher than 99.54% of US stocks with positive earnings.
  • In terms of volatility of its share price, LNTH is more volatile than just 14.33% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Lantheus Holdings Inc, a group of peers worth examining would be KRNT, JVA, CYBR, NOK, and CAAS.
  • Visit LNTH's SEC page to see the company's official filings. To visit the company's web site, go to www.lantheus.com.

LNTH Stock Price Chart Interactive Chart >

Price chart for LNTH

LNTH Price/Volume Stats

Current price $13.17 52-week high $21.42
Prev. close $13.00 52-week low $8.67
Day low $12.97 Volume 97,926
Day high $13.21 Avg. volume 531,167
50-day MA $12.46 Dividend yield N/A
200-day MA $13.33 Market Cap 880.69M

Lantheus Holdings, Inc. (LNTH) Company Bio


Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide. The company was founded in 1956 and is based in North Billerica, Massachusetts.

LNTH Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$13.17$11.98 -4%

Below please find a table outlining a discounted cash flow forecast for LNTH, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Lantheus Holdings Inc ranked in the 46th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for LNTH, they are:

  • Lantheus Holdings Inc's effective tax rate, as measured by taxes paid relative to net income, is at 163 -- greater than 98.64% of US stocks with positive free cash flow.
  • The weighted average cost of capital for the company is 11. This value is greater than 82.92% stocks in the Healthcare sector that generate free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-6%
1%-5%
2%-4%
3%-3%
4%-2%
5%-1%

USPH, MMSI, PAHC, IART, and AMGN can be thought of as valuation peers to LNTH, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


LNTH Latest News Stream


Event/Time News Detail
Loading, please wait...

LNTH Latest Social Stream


Loading social stream, please wait...

View Full LNTH Social Stream

Latest LNTH News From Around the Web

Below are the latest news stories about Lantheus Holdings Inc that investors may wish to consider to help them evaluate LNTH as an investment opportunity.

Lantheus files U.S. application for PET imaging agent for prostate cancer

Lantheus Holdings (LNTH), which merged with Progenics Pharmaceuticals (PGNX) in June, announces the filing of a U.S. marketing application seeking approval of PyL (18-F DCFPyL), a prostate-specific membrane antigen ((PSMA))-targeted positron emission tomography ((PET)) imaging agent for prostate cancer.The application includes a request for Priority Review which, if granted, will shorten...

Seeking Alpha | September 30, 2020

Lantheus Holdings to Present at the Wells Fargo 2020 Virtual Healthcare Conference

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced Mary Anne Heino, President and Chief Executive Officer, will present at the Wells Fargo 2020 Virtual Healthcare Conference at 4:00 p.m. ET on Thursday, Septembe

Business Wire | September 3, 2020

Lantheus's activation device for ultrasound agent OK'd in U.S

The FDA approves Lantheus's ([[LNTH]] -0.3%) for VIALMIX RFID an activation device for DEFINITY injectable suspension, an intravenous ultrasound enhancing agent.The RFID tag, which is affixed to the vial label, enables controlling the activation rate and time, ensuring reproducible activation of DEFINITY and thus reducing the risks related to operator or medication errors.A U.S. issued patent on the new VIALMIXRFID...

Seeking Alpha | August 12, 2020

Lantheus Holdings Inc (LNTH) Q2 2020 Earnings Call Transcript

Joining me today is our President and CEO, Mary Anne Heino, and our CFO, Bob Marshall. Before we get started, I'd like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements due to a variety of risks and uncertainties.

Yahoo | July 30, 2020

Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results

Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today reported financial results for its second quarter ended June 30, 2020.

Yahoo | July 30, 2020

Read More 'LNTH' Stories Here

LNTH Price Returns

1-mo 16.96%
3-mo -2.37%
6-mo -4.08%
1-year -37.05%
3-year -42.36%
5-year 268.91%
YTD -35.79%
2019 31.05%
2018 -23.47%
2017 137.79%
2016 154.44%
2015 N/A

Continue Researching LNTH

Here are a few links from around the web to help you further your research on Lantheus Holdings Inc's stock as an investment opportunity:

Lantheus Holdings Inc (LNTH) Stock Price | Nasdaq
Lantheus Holdings Inc (LNTH) Stock Quote, History and News - Yahoo Finance
Lantheus Holdings Inc (LNTH) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0173 seconds.